North American Drug Delivery Technologies Market worth $102.2 Billion By 2017

1
MarketsandMarkets Presents
North American Drug Delivery Technologies Market
worth 102.2 Billion By 2017
2

• The North American Drug Delivery Technologies
  Market (Metered Dose Inhalers, Needle-Free
  Injectors, Auto-Injectors, Nasal Sprays,
  Transdermal Patches, Nebulizers, Infusion Pumps,
  Drug Eluting Stents, Sustained Release, Ocular
  Implants) Forecasts to 2017 analyzes and studies
  the major market drivers, restraints, and
  opportunities in North America.
• Browse 95 market data tables with 28 figures
  spread through 267 pages and in-depth TOC on "
  North American Drug Delivery Technologies Market
  (Metered Dose Inhalers, Needle-Free Injectors,
  Auto-Injectors, Nasal Sprays, Transdermal
  Patches, Nebulizers, Infusion Pumps, Drug Eluting
  Stents, Sustained Release, Ocular Implants)
  Forecasts to 2017"
• http//www.marketsandmarkets.com/Market-Reports/n
  orth-american-drug-delivery-technologies-market-12
  09.html

3

Early buyers will receive 10 customization on
Reports.
4

• This report studies the North American Drug
  Delivery Technologies Market over the forecast
  period of 2012 - 2017.
• The North American market was valued at 66.7
  billion in 2012 and is poised to reach 102.2
  billion by 2017. The U.S. registered a higher
  market share, valued at 59.3 billion in 2012 and
  is expected to grow at a high single digit CAGR
  from 2012 to 2017. The Canadian market is also
  growing at a decent CAGR of 7.9, to reach 10.7
  billion by 2017.
• The U.S. Supreme courts decision to uphold the
  healthcare reforms is expected to substantially
  increase the number of insured citizens in the
  U.S. This will thereby boost the market for novel
  drug delivery technology based formulations and
  devices. In addition, the rising number of drug
  approvals by Health Canada, serves as an
  opportunity for the Canadian market.

5

• The acquisitions of Eurand Pharmaceuticals
  (Netherlands) by Aptalis Pharma(U.S.), Labopharm
  (Canada) by Paladin Labs (Canada), and CIMA Labs
  (U.S.) and Cephalon by Teva Pharmaceuticals
  (Israel) constitute the major developments in the
  North American market. Also, there are
  significant developments in the field of targeted
  drug delivery (using liposomes and nanoparticle
  drug carriers) owing to the advancements in
  polymers and biopolymers technology for small
  molecules, macromolecules, and prodrugs.
• The growth of the market is driven by the
  increasing adoption of drug delivery technologies
  by pharmaceutical and medical device companies in
  North America, and greater patient acceptability
  of drug delivery products. The opportunities for
  the growth of this market include developments of
  drug delivery technologies for non-conventional
  therapeutic applications and for use in home
  setting.

6

• Other factors like collaborations of drug
  delivery firms with pharmaceutical firms also
  offer opportunities to the drug delivery firms,
  as they could assist pharmaceutical companies
  with their manufacturing services technology
  platforms, product development, and regulatory
  procedures. However, in the past and present,
  product recalls of drug delivery products is one
  factor that hampered the growth of this market
  and also raised concerns on RD expenditure for
  development of such products.
• This research report categorizes the North
  American drug delivery technologies market by
  routes of administration it includes oral,
  pulmonary, transdermal, injectable, ocular,
  nasal, topical, implantable, and transmucosal
  technologies. All these market segments are
  further divided into sub-segments that comprise
  of formulations or devices, to provide exhaustive
  value analysis for the years 2010, 2011, 2012,
  and forecast to 2017. The North American market
  for oral drug delivery technologies was estimated
  at 25.4 billion in 2012 and is expected to grow
  at a healthy CAGR of 8.6 from 2012 to 2017.

7

• Oral technologies offer easier and cost-effective
  reformulation strategies hence they occupy the
  largest share in the market. On the other hand,
  pulmonary technologies market is expected to grow
  at the highest CAGR of 11.8, due to the
  increased adoption rates of pulmonary devices and
  their expanding applications. This market is
  poised to reach 23.1 billion by 2017.
• Key players in the market are 3M Company (U.S.),
  Aptalis Pharma, Inc. (U.S.), Baxter
  International, Inc. (U.S.), Becton Dickinson
  Co. (U.S.), Catalent Pharma Solutions (U.S.),
  Cipher Pharmaceuticals (Canada), Dow Chemical
  Company (U.S.), Endo Pharmaceuticals (U.S.),
  Johnson Johnson (U.S.), Nektar Therapeutics
  (U.S.), OptiNose (U.S.), QLT (Canada), and
  Valeant Pharmaceuticals (Canada).

8
About MarketsandMarkets
Markets and Markets is a global market research
and consulting company based in the U.S. We
publish strategically analyzed market research
reports and serve as a business intelligence
partner to Fortune 500 companies across the
world. Markets and Markets also provides
multi-client reports, company profiles,
databases, and custom research services. They
cover thirteen industry verticals, including
advanced materials, automotive and
transportation, banking and financial services,
biotechnology, chemicals, consumer goods, energy
and power, food and beverages, industrial
automation, medical devices, pharmaceuticals,
semiconductor and electronics, and
telecommunications and IT. We at Markets and
Markets are inspired to help our clients grow by
providing apt business insight with our huge
market intelligence repository.
9
Contact Us
Mr. RohanNorth - Dominion Plaza, 17304 Preston
Road, Suite 800, Dallas, TX 75252Tel
1-888-6006-441Email sales_at_marketsandmarkets.com
 MarketsandMarkets Blog http//twitter.com/marke
tsmarkets
http//www.linkedin.com/company/marketsandmarkets